{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:14:07Z","timestamp":1794021247754,"version":"4.8.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Antibiotics are commonly used during pregnancy. However, physiological changes during pregnancy can affect the pharmacokinetics of drugs, including antibiotics, used during this period. Pharmacokinetic evaluations have shed light on how antibiotics are affected during pregnancy and have influenced dosing recommendations in this context.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A narrative review was conducted and included reports providing data reflecting drug distribution and exposure in the context of pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Pharmacokinetic parameters of antibiotics in pregnancy and transplacental passage of antibiotics are comprehensively presented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Knowledge about the impact on pharmacokinetics and fetal exposure is especially helpful for complicated or severe infections, including intra-amniotic infection and sepsis in pregnancy, where both mother and fetus are at risk. Further studies are warranted to consolidate the role of therapeutic drug monitoring in complicated or severe infections in pregnant patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000950","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T18:01:01Z","timestamp":1639332061000},"page":"50-64","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Understanding the Pharmacokinetics of Antibiotics in Pregnancy: Is There a Role for Therapeutic Drug Monitoring? A Narrative Review"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-5745","authenticated-orcid":false,"given":"Jana","family":"Stojanova","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia;"},{"name":"Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valpara\u00edso, Valpara\u00edso, Chile;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Arancibia","sequence":"additional","affiliation":[{"name":"Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valpara\u00edso, Valpara\u00edso, Chile;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital;"},{"name":"Faculty of Medicine and Health, Westmead Clinical School, The University of Sydney; and"},{"name":"Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/FTD.0b013e318261c372","article-title":"Therapeutic drug monitoring in pregnancy","volume":"34","author":"Matsui","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"Plos Med"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fped.2014.00009","article-title":"Obstetric pharmacokinetic dosing studies are urgently needed","volume":"2","author":"McCormack","year":"2014","journal-title":"Front Pediatr"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1060028018817935","article-title":"Common bacterial and viral infections: review of management in the pregnant patient","volume":"53","author":"Rac","year":"2019","journal-title":"Ann Pharmacother"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1213\/ANE.0000000000001143","article-title":"Pharmacokinetics and pharmacodynamics of drugs commonly used in pregnancy and parturition","volume":"122","author":"Ansari","year":"2016","journal-title":"Anesth Analg"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/AOG.0000000000002236","article-title":"Committee opinion no. 712: intrapartum management of intraamniotic infection","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/AOG.0000000000002833","article-title":"ACOG practice bulletin no. 199: use of prophylactic antibiotics in labor and delivery","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R9-20250603","first-page":"e19","article-title":"Streptococcal early-onset disease in newborns: ACOG committee opinion, number 782","volume":"134","author":"Prevention of Group","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00003088-197904040-00003","article-title":"Pharmacokinetics of antibiotics in pregnancy and labour","volume":"4","author":"Philipson","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/clinids\/7.3.287","article-title":"Pharmacokinetics and safety of antimicrobial agents during pregnancy","volume":"7","author":"Chow","year":"1985","journal-title":"Rev Infect Dis"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/phar.1649","article-title":"A review of antibiotic use in pregnancy","volume":"35","author":"Bookstaver","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.clinthera.2016.08.005","article-title":"Principles of anti-infective dosing in pregnancy","volume":"38","author":"Patil","year":"2016","journal-title":"Clin Ther"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/138920009788897993","article-title":"Variation of drug kinetics in pregnancy","volume":"10","author":"Pavek","year":"2009","journal-title":"Curr Drug Metab"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11095-018-2352-2","article-title":"Pregnancy-associated changes in pharmacokinetics and their clinical implications","volume":"35","author":"Koren","year":"2018","journal-title":"Pharm Res"},{"key":"R16-20250603","first-page":"919","article-title":"The need for adjustment of dosage regimen of penicillin V during pregnancy","volume":"81","author":"Heikkil\u00e4","year":"1993","journal-title":"Obstet Gynecol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/136.3.370","article-title":"Pharmacokinetics of ampicillin during pregnancy","volume":"136","author":"Philipson","year":"1977","journal-title":"J Infect Dis"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9378(93)90515-K","article-title":"Pharmacokinetics of ampicillin and sulbactam in pregnancy","volume":"168","author":"Chamberlain","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.clpt.6100126","article-title":"Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies","volume":"81","author":"Andrew","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.ajog.2007.05.018","article-title":"Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes","volume":"198","author":"Muller","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1365-2125.2008.03292.x","article-title":"The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women","volume":"66","author":"Muller","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2165\/00003088-198712020-00004","article-title":"Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women","volume":"12","author":"Philipson","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2710.2007.00864.x","article-title":"Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women","volume":"32","author":"Popovi\u0107","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1128\/AAC.02613-13","article-title":"Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery","volume":"58","author":"Elkomy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0002-9378(16)32526-1","article-title":"Pharmacokinetics of cefuroxime in pregnancy","volume":"142","author":"Philipson","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/AAC.37.1.54","article-title":"Pharmacokinetics and protein binding of ceftriaxone during pregnancy","volume":"37","author":"Bourget","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/AAC.00771-09","article-title":"Pharmacokinetic properties of azithromycin in pregnancy","volume":"54","author":"Salman","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1128\/AAC.00717-11","article-title":"Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age","volume":"56","author":"Fischer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1128\/AAC.01017-09","article-title":"Pharmacokinetics of clindamycin in pregnant women in the peripartum period","volume":"54","author":"Muller","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/14767058.2010.497573","article-title":"Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis","volume":"24","author":"Wang","year":"2011","journal-title":"J Matern-Fetal Neonatal"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.AOG.0000151106.87930.1a","article-title":"High compared with standard gentamicin dosing for chorioamnionitis: a comparison of maternal and fetal serum drug levels","volume":"105","author":"Locksmith","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/infdis\/135.6.925","article-title":"Maternal-fetal pharmacological activity of amikacin","volume":"135","author":"Bernard","year":"1977","journal-title":"J Infect Dis"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/030006057700500412","article-title":"Clinical pharmacology of amikacin sulphate: blood, urinary and tissue concentrations in the terminal stage of pregnancy","volume":"5","author":"Flores-Mercado","year":"1977","journal-title":"J Int Med Res"},{"key":"R34-20250603","first-page":"908","article-title":"Transplacental passage of vancomycin during the second trimester of pregnancy","volume":"78","author":"Bourget","year":"1991","journal-title":"Obstet Gynecol"},{"key":"R35-20250603","first-page":"578","article-title":"Studies on the pharmacokinetics of the compound preparation sulfamerazine\/trimethoprim (Berlocombin-200) in pregnancy [in German]","volume":"37","author":"Peiker","year":"1982","journal-title":"Die Pharmazie"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/138620710791516003","article-title":"Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection","volume":"13","author":"Nemutlu","year":"2010","journal-title":"Comb Chem High Throughput Screen"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1601724","DOI":"10.1183\/13993003.01724-2016","article-title":"Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis","volume":"49","author":"Van Kampenhout","year":"2017","journal-title":"Eur Respir J"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000238369","article-title":"Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy","volume":"31","author":"Voigt","year":"1985","journal-title":"Chemotherapy"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jac\/28.3.419","article-title":"Pharmacokinetics of piperacillin during pregnancy","volume":"28","author":"Heikkil\u00e4","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0301-2115(97)00150-4","article-title":"Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination","volume":"76","author":"Bourget","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1 pt 1","key":"R41-20250603","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0002-9378(95)90107-8","article-title":"Renal elimination of ceftazidime during pregnancy","volume":"172","author":"Nathorst-B\u00f6\u00f6s","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.36.12.2652","article-title":"Pharmacokinetics and transplacental passage of imipenem during pregnancy","volume":"36","author":"Heikkil\u00e4","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-2125.2006.02827.x","article-title":"Protein binding of cefazolin is saturable in vivo both between and within patients","volume":"63","author":"Vella-Brincat","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1358\/mf.2009.31.1.1338413","article-title":"Cefazolin plasma protein binding saturability during pregnancy","volume":"31","author":"Allegaert","year":"2009","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejogrb.2017.01.022","article-title":"Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section?","volume":"210","author":"Kram","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000000789","article-title":"Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial","volume":"125","author":"Maggio","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/AOG.0b013e31820b95e4","article-title":"Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery","volume":"117","author":"Pevzner","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/sur.2012.040","article-title":"Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug","volume":"14","author":"Stitely","year":"2013","journal-title":"Surg Infect"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"415.e1","DOI":"10.1016\/j.ajog.2015.05.030","article-title":"Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women","volume":"213","author":"Swank","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"541.e1","DOI":"10.1016\/j.ajog.2015.06.034","article-title":"Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery","volume":"213","author":"Young","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/AOG.0b013e3182238c31","article-title":"ACOG Practice Bulletin No. 120: use of prophylactic antibiotics in labor and delivery","volume":"117","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/jp.2016.210","article-title":"Optimal administration of cefazolin prophylaxis for cesarean delivery","volume":"37","author":"Duffield","year":"2017","journal-title":"J Perinatol"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/AAC.22.5.816","article-title":"Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults","volume":"22","author":"Pollock","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"R54-20250603","first-page":"124","article-title":"Antibiotic concentration in maternal blood, cord blood, and placental membranes in chorioamnionitis","volume":"72","author":"Gilstrap","year":"1988","journal-title":"Obstet Gynecol"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2005.07.098","article-title":"Optimal timing of ampicillin administration to pregnant women for establishing bactericidal levels in the prophylaxis of Group B Streptococcus","volume":"194","author":"Colombo","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mob.2003.141","article-title":"Maternal and transplacental pharmacokinetics of azithromycin","volume":"188","author":"Ramsey","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"812.e1","DOI":"10.1016\/j.ajog.2015.01.015","article-title":"Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis","volume":"212","author":"Sutton","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM197306072882307","article-title":"Transplacental passage of erythromycin and clindamycin","volume":"288","author":"Philipson","year":"1973","journal-title":"N Engl J Med"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"33","DOI":"10.17772\/gp\/1896","article-title":"The placental transfer of erythromycin in human pregnancies with group B streptococcal infection","volume":"86","author":"Bulska","year":"2015","journal-title":"Ginekol Pol"},{"key":"R60-20250603","first-page":"960","article-title":"Transplacental passage of clindamycin from mother to neonate","volume":"36","author":"Wear","year":"2016","journal-title":"J Perinatol Off J Calif Perinat Assoc"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"352.e1","DOI":"10.1016\/j.ajog.2014.01.019","article-title":"Transplacental passage of vancomycin from mother to neonate","volume":"210","author":"Onwuchuruba","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijantimicag.2010.03.011","article-title":"Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone","volume":"36","author":"Ozyuncu","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl 1","key":"R63-20250603","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"L\u00f6fmark","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/GRF.0b013e31818091cd","article-title":"Once-daily dosing of gentamicin in obstetrics and gynecology","volume":"51","author":"Ward","year":"2008","journal-title":"Clin Obstet Gynecol"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14767058.2017.1306049","article-title":"Transplacental passage of vancomycin","volume":"31","author":"Towers","year":"2018","journal-title":"J Matern-Fetal Neonatal Med."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00002018-200326130-00002","article-title":"Use of antibiotic and analgesic drugs during lactation","volume":"26","author":"Bar-Oz","year":"2003","journal-title":"Drug Saf"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.reprotox.2019.02.002","article-title":"Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: a systematic review and meta-analysis","volume":"85","author":"Acar","year":"2019","journal-title":"Reprod Toxicol"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11095-018-2383-8","article-title":"Pregnancy outcomes following exposure to quinolone antibiotics\u2014a systematic-review and meta-analysis","volume":"35","author":"Ziv","year":"2018","journal-title":"Pharm Res"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/1471-0528.15119","article-title":"The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis","volume":"125","author":"Yefet","year":"2018","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.earlhumdev.2019.05.020","article-title":"The transplacental passage of commonly used intrapartum antibiotics and its impact on the newborn management: a narrative review","volume":"135","author":"Viel-Theriault","year":"2019","journal-title":"Early Hum Dev"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/apm.12951","article-title":"Antibiotic therapy as personalized medicine - general considerations and complicating factors","volume":"127","author":"Moser","year":"2019","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijoa.2018.04.010","article-title":"Sepsis in pregnancy and the puerperium","volume":"36","author":"Burlinson","year":"2018","journal-title":"Int J Obstet Anesth"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:27:31Z","timestamp":1748971651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000950","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}